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Abstract: α-Lipoic acid (LA) is a thiol with antioxidant properties that protects against 
oxidative stress-induced apoptosis. LA is absorbed from the diet, taken up by cells and 
tissues, and subsequently reduced to dihydrolipoic acid (DHLA). In view of the recent 
application  of  DHLA  as  a  hydrophilic  nanomaterial  preparation,  determination  of  its 
biosafety profile is essential. In the current study, we examined the cytotoxic effects of 
DHLA  on  mouse  embryos  at  the  blastocyst  stage,  subsequent  embryonic  attachment   
and  outgrowth  in  vitro,  in  vivo  implantation  by  embryo  transfer,  and  early  embryonic 
development  in  an  animal  model.  Blastocysts  treated  with  50  μM  DHLA  exhibited 
significantly  increased  apoptosis  and  a  corresponding  decrease  in  total  cell  number. 
Notably, the implantation success rates of blastocysts pretreated with DHLA were lower 
than that of their control counterparts. Moreover, in vitro treatment with 50 μM DHLA was 
associated  with  increased  resorption  of  post-implantation  embryos  and  decreased  fetal 
weight. Data obtained using an in vivo mouse model further disclosed that consumption of 
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drinking water containing 100 μM DHLA led to decreased early embryo development, 
specifically, inhibition of development to the blastocyst stage. However, it appears that 
concentrations of DHLA lower than 50 μM do not exert a hazardous effect on embryonic 
development.  Our  results  collectively  indicate  that  in  vitro  and  in  vivo  exposure  to 
concentrations of DHLA higher than 50 μM DHLA induces apoptosis and retards early 
pre- and  post-implantation development,  and support  the potential of  DHLA  to  induce 
embryonic cytotoxicity. 
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1. Introduction 
α-Lipoic acid (LA), a type of thioctic acid, is naturally synthesized by some plants and animals, 
including humans [1]. Endogenous LA acts as a cofactor for important mitochondrial enzymes and 
other multienzyme complexes, including those of branched-chain α-keto acid, pyruvate dehydrogenase, 
α-ketoglutarate  dehydrogenase,  and  glycine  decarboxylase  [2,3].  LA  absorbed  from  food  intake 
crosses the blood-brain barrier, is transported and taken up by cells, and subsequently converted to the 
reduced form, dihydrolipoic acid (DHLA) [4]. Although LA and DHLA display pro-oxidant properties 
under specific conditions, both compounds additionally act as strong antioxidants [5,6]. Recent studies 
showed that LA and DHLA possess anti- or proapoptotic properties. These compounds function in 
various cell types to block or prevent oxidative stress-induced apoptosis but promote apoptosis in 
several cancer cell lines [7–12]. In addition, our recent study showed that DHLA (50–100 μM) induces 
apoptotic  processes  in  mouse  embryonic  stem  cells  (ESC-B5)  [13].  DHLA  (50–100  μM)  directly 
increased the reactive oxygen species (ROS) content in ESC-B5 cells, along with a significant increase 
in cytoplasmic free calcium and nitric oxide (NO) levels, loss of mitochondrial membrane potential 
(MMP), activation of caspases-9 and -3, and cell death. Our results collectively indicate that DHLA at 
concentrations  of  50–100  μM  triggers  apoptosis  of  ESC-B5  cells,  which  involves  both  ROS  and   
NO [13]. The ambiguous issue of whether LA and DHLA are pro-/antioxidant or pro-/antiapoptosis 
agents requires further investigation. DHLA is an important capping ligand utilized in the preparation 
of  nanoparticles  for  cellular  labeling  and  tracking,  including  detection  of  tracers  in  embryonic 
development investigation [14–16]. Thus, it is crucial to determine the safety and toxicity of DHLA, 
both in cells and embryonic development. 
Apoptosis plays an important role in development and disease [17]. While several studies have 
shown that apoptosis functions in normal embryonic development [18–20], mechanistically diverse 
teratogens can induce excessive apoptosis in early embryos, leading to developmental injury [21–25]. 
Previous studies have demonstrated that DHLA induces apoptosis in mammalian cells, including lung 
cancer and HL-60 leukemia cells [12,26]. In the present study, we further investigated whether the 
DHLA has cytotoxic effects on embryonic development, using mouse blastocysts as the assay model. 
Our results showed that DHLA suppresses embryonic cell proliferation during the blastocyst stage 
predominantly  via  inducing  apoptosis  in  the  inner  cell  mass  (ICM),  but  has  no  effect  on  the 
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trophectoderm (TE). The effects of DHLA on subsequent developmental injury of blastocysts in vitro 
and embryo transfer in vivo were additionally examined.   
2. Results 
2.1. Effects of DHLA on Mouse Blastocysts 
To investigate the possibility of DHLA-induced cytotoxicity, we treated mouse blastocysts with 25, 
50 or 100 μM DHLA at 37 ° C for 24 h, and monitored apoptosis using the TUNEL method. Cellular 
apoptosis was evident in blastocysts treated with 50 μM DHLA (Figure 1A). Quantitative analysis 
revealed ~2.5 to 7.5-fold more apoptotic cells in 50–100 μM DHLA-treated blastocysts, compared 
with untreated control cells (Figure 1B). Clearly, DHLA induces apoptosis in mouse blastocysts within 
the 50–100 μM concentration range. 
Figure 1. Dihydrolipoic acid (DHLA) induces apoptosis in mouse blastocysts. (A) Mouse 
blastocysts were treated with DHLA (25, 50 or 100 μM) for 24 h or left untreated, and 
apoptosis examined via TUNEL staining. Cells were visualized using light microscopy. 
TUNEL-positive  cells  are  depicted  in  black;  (B)  The  mean  number  of  apoptotic 
(TUNEL-positive) cells per blastocyst was calculated. Values are presented as means ±  
SEM of ten determinations. *** P < 0.001 versus the control group. 
 
2.2. Effects of DHLA on Cell Proliferation 
Differential staining, followed by cell counting, was used to assess cell proliferation in blastocysts 
either treated with 25, 50 or 100 μM DHLA for 24 h or left untreated. We observed significantly lower 
cell numbers in 50 μM DHLA-treated blastocysts, compared with control cells (Figure 2A). Annexin 
V staining revealed markedly higher numbers of Annexin V-positive/PI-negative (apoptotic) cells in 
the ICM of treated blastocysts versus controls, but no such differences in the trophectoderm (TE) 
(Figure 2B). Our experiments show that 50–100 μM DHLA induces significant apoptosis in the ICM, 
but not TE, of mouse blastocysts, further supporting the theory that DHLA impairs the developmental 
potential of blastocysts. Int. J. Mol. Sci. 2012, 13  3991 
 
Figure 2. Effects of DHLA on blastocyst viability. Mouse blastocysts were treated with or 
without DHLA (25, 50 or 100 μM) for 24 h. (A) The total number of cells per blastocyst 
and cell numbers in the inner cell mass (ICM) and trophectoderm (TE) were counted;   
(B) The percentages of Annexin V-positive/PI-negative cells in blastocysts of each group 
were  examined.  Data  are  based  on  at  least  200  blastocyst  samples  from  each  group.   
*** P < 0.001 versus the control group. 
 
 
2.3. Effects of DHLA on Mouse Embryonic Developmental Potential in Vitro 
Untreated control morulae displayed 80% development to blastocysts, whereas only 52% of those 
treated with 50 μM DHLA developed into blastocysts under our experimental conditions (Figure 3A). 
To further determine the effects of DHLA on post-implantation events in vitro, we treated blastocysts 
with or without 25, 50 or 100 μM DHLA, and analyzed subsequent development for 8 days in culture. 
Importantly, the rate of embryo attachment to fibronectin-coated culture dishes and lack of further 
development (attachment only group) has no any effects by treatment with DHLA (Figure 3B). However, 
DHLA-pretreated  blastocysts  displayed  a  lower  incidence  of  post-implantation  developmental 
milestones (Figure 3B). Our results clearly indicate that DHLA affects the in vitro potential of blastocysts 
to develop into post-implantation embryos. Int. J. Mol. Sci. 2012, 13  3992 
 
Figure 3. In vitro development of mouse embryos exposed to DHLA at the blastocyst stage. 
(A) Mouse morulae were treated with DHLA (25, 50 or 100 μM) for 24 h or left untreated, 
and cultured for an additional 24 h at 37 ° C. Blastocysts were counted and percentages 
calculated; (B) Mouse blastocysts were treated with DHLA (25, 50 or 100 μM) for 24 h or 
left  untreated  and  cultured  for  7  days  post-treatment.  Blastocysts  were  identified  as 
attachment  only,  ICM(+),  ICM(++),  and  ICM(+++)  via  morphological  assessment,  as 
described  in  Materials  and  Methods.  Values  are  presented  as  means  ±   SEM  of  eight 
determinations. *** P < 0.001 versus the control group. 
 
 
2.4. Effects of DHLA on the Developmental Potential of Blastocysts in Vivo 
To determine the effects of DHLA on blastocyst development in vivo, we transferred control and 
DHLA-pretreated mouse blastocysts, and examined the uterine content at 13 days post-transfer (day 18 
post-coitus). The implantation ratios in the 50–100 μM DHLA-pretreated groups were significantly 
lower than that of the untreated control  group  (Figure 4A). Embryos  that  implanted but  failed to 
develop were subsequently resorbed. However, the proportion of implanted embryos that failed to 
develop normally was markedly higher in the group treated with 50–100 μM DHLA (Figure 4A). 
Interestingly, no significant differences in placental weight were observed between the DHLA-treated 
and untreated groups (Figure 4B). However, fetal weight was lower in the 100 μM DHLA-treated 
group compared to the control group (479 ±  61 mg versus 611 ±  68 mg, respectively). Previous studies, 
including a recent report by our group, showed that 35–40% of fetuses weigh more than 600 mg, and Int. J. Mol. Sci. 2012, 13  3993 
 
the average weight of total surviving fetuses is about 600 ±  12 mg in the untreated control group at   
day  18  of  pregnancy  in  a  mouse  embryo  transfer  assay  [23,27–30].  Fetal  weight  is  an  important 
indicator of developmental status, and the average fetal weight of the untreated control group is used 
as a key marker of development of blastocysts treated with 100 μM DHLA. Interestingly, only 5.8% of 
the fetuses in the 100 μM DHLA-pretreated group weighed more than 600 mg (indicative of successful 
embryonic and fetal development), whereas 43% of control fetuses exceeded this threshold (Figure 4C). 
These observations collectively indicate that exposure to high concentrations of DHLA (such as 100 μM) 
at the blastocyst stage reduces embryo implantation and the potential for post-implantation development. 
Figure 4. Effects of DHLA on in vivo implantation, resorption, fetal survival and fetal 
weights of mouse blastocysts. (A) Mouse blastocysts were treated with DHLA (25, 50 or 
100 μM) for 24 h or left untreated. Implantations, resorptions and surviving fetuses were 
analyzed,  as  described  in  Materials  and  Methods.  The  percentage  of  implantations 
represents the number of implantations per number of transferred embryos ×  100. The 
percentage  of  resorptions  or  surviving  fetuses  signifies  the  number  of  resorptions  or 
surviving fetuses per number of implantations ×  100; (B) Placental weights of 40 recipient 
mice were measured; (C) Weight distribution of surviving fetuses on day 18 post-coitus. 
Surviving  fetuses  were  obtained  by  embryo  transfer  of  control  and  DHLA-pretreated 
blastocysts,  as  described  in  Materials  and  Methods  (320  total  blastocysts  across   
40 recipients). * P < 0.05 and *** P < 0.001 versus the DHLA-free group. 
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2.5. Disruption of Blastocyst Development by DHLA in Vivo 
Next, we examined the effects of DHLA on blastocyst development in an animal model. Female 
mice were fed a standard diet and drinking water supplemented with or without DHLA (25, 50 or   
100 μM). DHLA consumption led to significant apoptosis and decreased cell proliferation in mouse 
blastocysts (Figure 5A,B). In addition, DHLA inhibited embryonic development to the blastocyst stage, 
causing frequent termination at the 2–16 cell or morula stage or degradation (Figure 5C). These results 
further validate the theory that exposure to high concentrations of DHLA (50–100 μM) through intake 
is potentially hazardous for mouse embryonic development.   
Figure 5. Effects of dietary DHLA on apoptosis and blastocyst development in an animal 
model. For the duration of the experiment, randomly selected female mice were fed a 
standard diet and drinking water supplemented with or without DHLA (25, 50 or 100 μM). 
After 24 h, female mice were mated overnight with a single fertile male of the same strain. 
Blastocysts  were  obtained  by  flushing  the  uterine  horn  on  day  4  after  mating.   
(A) Apoptosis of mouse blastocysts was examined by TUNEL staining followed by light 
microscopy,  and  the  mean  number  of  apoptotic  (TUNEL-positive)  cells  per  blastocyst 
calculated;  (B)  The  total  numbers  of  cells  per  blastocyst  were  counted;  (C)  Embryos 
obtained  from  mouse  uterine  horns  on  day  4  were  examined  for  comparison  of  the 
developmental stages. Data are presented as a percentage of total embryos. Values are 
presented as means ±  SEM (n = 6). *** P < 0.001 versus untreated control group. 
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During  the  complex  and  precisely  orchestrated  embryonic  development  process,  chemical  or 
physical injury can affect normal development and lead to malformation or miscarriage of the embryo. 
Thus, it is important to establish the possible teratogenic effects of various agents, including natural 
chemical compounds or capping ligands for the preparation of fluorescence nanoparticles, which could 
be developed as embryonic development tracers. 
During normal embryogenesis, apoptosis (a unique morphological pattern of cell death) functions to 
clear abnormal or redundant cells in preimplantation embryos [31,32]. Apoptotic processes do not 
occur prior to the blastocyst stage during normal mouse embryonic development [33], and induction of 
apoptosis during the early stages of embryogenesis (i.e., following exposure to a teratogen) causes 
embryonic  developmental  injury  [22,23,28,34,35].  In  the  present  study,  we  investigated  whether 
DHLA  adversely  affects  the  blastocyst  stage  of  mouse  embryos  and  subsequent  early  pre-  and 
post-implantation embryonic development. Preliminary data showed that DHLA treatment for 24 h 
induces apoptosis in mouse blastocysts (Figure 1). Based on this finding, we further analyzed the 
effects of DHLA on embryonic development by incubating blastocysts in medium containing 25, 50 or 
100 μM DHLA for 24 h. DHLA treatment decreased cell viability in mouse blastocysts via apoptosis 
(Figures 1 and 2). Treatment of mouse blastocysts with 50 μM DHLA induced apoptosis, as evident 
from  TUNEL  staining  data  (Figure  1).  Dual  differential  staining  results  further  disclosed  that 
DHLA-induced cell loss and apoptosis occurs primarily in the ICM (Figure 2).   Int. J. Mol. Sci. 2012, 13  3996 
 
The TE arises from the trophoblast at the blastocyst stage and develops into a sphere of epithelial 
cells surrounding the ICM and blastocoel. These cells contribute to the placenta, and are required for 
development of the mammalian conceptus [36]. Thus, reduction in the TE cell lineage may suppress 
implantation  and  embryonic  viability  [37,38].  However,  in  our  experiments,  DHLA  induced  cell 
apoptosis  specifically  in  the  ICM  and  not  TE,  indicative  of  deleterious  effects  on  embryonic 
development  in  vitro,  implantation  and  post-implantation  development  in  vivo  or  disruption  of 
blastocyst development in an animal model (Figures 2–5). Previous studies have reported a reduction 
of  at  least  ~30%  in  the  number  of  cells  in  the  ICM,  associated  with  high  risk  of  fetal  loss  or 
developmental injury, even in cases where the implantation rate and TE cell numbers are normal [39]. 
In addition, the ICM cell number is essential for proper implantation, and reduction in the cell lineage 
may decrease embryonic viability  [37,38]. Our observation that DHLA treatment reduced the cell 
number and promoted apoptosis in the ICM of mouse blastocysts, but had no effect on the TE (Figure 2), 
led  us  to  investigate  the  possibility  that  DHLA  induces  mortality  and/or  developmental  delay  in 
post-implantation mouse embryos in vitro and in vivo. DHLA-treated blastocysts displayed decreased 
embryonic  development  and  increased  embryonic  death  in  vitro  and  reduced  implantation  in  vivo 
(Figures 3 and 4). Our study results obtained using an animal assay model signify that DHLA exposure 
through dietary intake has the potential to cause hazardous effects on mouse embryonic development 
(Figure 5). These study results imply that development and preparation of fluorescence nanoparticles 
using  DHLA  as  a  capping  ligand  has  a  latent  ability  to  cause  cytotoxicity  and  injury  in   
embryonic development. 
4. Experimental Section 
4.1. Materials   
Pregnant mare’s serum gonadotropin (PMSG), Bovine serum albumin (BSA), sodium pyruvate and 
dihydrolipoic acid were purchased from Sigma (St. Louis, MO, USA). Human chorionic gonadotropin 
(hCG) was obtained from Serono (NV Organon Oss, the Netherlands). The TUNEL in situ cell death 
detection kit was obtained from Roche (Mannheim, Germany) and CMRL-1066 medium was from 
Gibco Life Technologies (Grand Island, NY, USA). 
4.2. Collection of Mouse Morulas and Blastocysts 
ICR mice were from National Laboratory Animal Center (Taiwan). This research was also approved 
by the Animal Research Ethics Board of Chung Yuan Christian University (Taiwan). All animals 
received  humane  care,  as  outlined  in  the  Guidelines  for  Care  and  Use  of  Experimental  Animals 
(Canadian  Council  on  Animal  Care,  Ottawa,  1984).  All  mice  were  maintained  on  breeder  chow 
(Harlan  Teklad  chow)  with  food  and  water  available  ad  libitum.  Housing  was  in  standard   
28 cm ×  16 cm ×  11 cm (height) polypropylene cages with wire-grid tops and kept under a 12 h· day/12 h 
night regimen. Nulliparous females (6–8 weeks old) were superovulated by injection of 5 IU PMSG 
followed 48 h later by injection of 5 IU hCG, and then mated overnight with a single fertile male of the 
same strain. The day a vaginal plug was found was defined as day 0 of gestation. Plug-positive females 
were  separated  for  experimentation.  Morulas  were  obtained  by  flushing  the  uterine  tubes  on  the Int. J. Mol. Sci. 2012, 13  3997 
 
afternoon of gestation day 3, and blastocysts were obtained by flushing the uterine horn on day 4; in 
both cases the flushing solution consisted of CMRL-1066 culture medium containing 1 mM glutamine 
and 1 mM sodium pyruvate.  The concentration of glucose in this medium was 5 mM.  Expanded 
blastocysts from different females were pooled and randomly selected for experiments.   
4.3. DHLA Treatment and TUNEL Assay 
Blastocysts were incubated in medium containing the indicated concentrations of DHLA for 24 h. 
For  apoptosis  detection,  embryos  were  washed  in  DHLA-free  medium,  fixed,  permeabilized  and 
subjected to TUNEL labeling using an in situ cell death detection kit (Roche Molecular Biochemicals, 
Mannheim,  Germany)  according  to  the  manufacturer’s  protocol.  Photographic  images  were  taken 
under bright field illumination using a fluorescence microscope. 
4.4. DHLA Treatment and Cell Proliferation 
Blastocysts were incubated with or without culture medium containing 0, 25, 50 or 100 μM DHLA. 
After 24 h they were washed with DHLA-free medium and dual differential staining was used to 
facilitate  counting  of  cell  numbers  in  the  inner  cell  mass  (ICM)  and  trophectoderm  (TE)  [37]. 
Blastocysts were incubated in 0.4% pronase in M2-BSA medium (M2 medium containing 0.1% bovine 
serum albumin) for removal of the zona pellucida. The denuded blastocysts were exposed to 1 mM 
trinitrobenzenesulphonic acid (TNBS) in BSA-free M2 medium containing 0.1% polyvinylpyrrolidone 
(PVP) at 4 ° C for 30 min, and then washed with M2 medium [40]. The blastocysts were further treated 
with 30 μg/mL anti-dinitrophenol-BSA complex antibody in M2-BSA at 37 °C  for 30 min, and then 
with M2 medium supplemented with 10% whole guinea-pig serum as a source of complement, along 
with  20  μg/mL  bisbenzimide  and  10  μg/mL  propidium  iodide  (PI),  at  37  °C   for  30  min.  The 
immunolysed blastocysts were gently transferred to slides and protected from light before observation. 
Under UV light excitation, the ICM cells (which take up bisbenzimidine but exclude PI) appeared blue, 
whereas the TE cells (which take up both fluorochromes) appeared orange-red. Since multinucleated 
cells  are  not  common  in  preimplantation  embryos  [41],  the  number  of  nuclei  was  considered  to 
represent an accurate measure of the cell number. 
4.5. Annexin V Staining 
Blastocysts were incubated in 25, 50 or 100 μM DHLA for 24 h, washed with DHLA-free culture 
medium,  and  then  stained  using  an  Annexin  V-FLUOS  staining  kit  (Roche),  according  to  the 
manufacturer's instructions. Briefly, the blastocysts were incubated in M2-BSA for removal of the zona 
pellucida, washed with PBS plus 0.3% BSA, and then incubated for 60 min with a mixture of 100 μL 
binding buffer, 1  μL  fluorescein  isothiocyanate  (FITC)-conjugated Annexin V and 1  μL PI. After 
incubation,  the  embryos  were  washed  and  photographed  using  a  fluorescence  microscope  under 
fluorescent  illumination.  Cells  staining  Annexin  V+/PI−  were  considered  apoptotic,  while  those 
staining Annexin V+/PI+ were considered necrotic. Int. J. Mol. Sci. 2012, 13  3998 
 
4.6. Morphological Analysis of Embryonic Development 
Blastocysts  were  cultured  according  to  a  modification  of  the  previously  reported  method  [42]. 
Briefly, embryos were cultured in 4-well multidishes at 37 ° C. For group culture, four embryos were 
cultured per well. The basic medium consisted of CMRL-1066 supplemented with 1 mM glutamine 
and 1 mM sodium pyruvate plus 50 IU/mL penicillin and 50 mg/mL streptomycin (hereafter called 
culture  medium).  For  treatments,  the  embryos  were  cultured  with  the  indicated  concentrations  of 
DHLA for 24 h in serum-free medium. Thereafter, the embryos were cultured for 3 days in culture 
medium supplemented with 20% fetal calf serum, and for 4 days in culture medium supplemented with 
20% heated-inactivated human placental cord serum, for a total culture time of 8 days from the onset 
of  treatment.  Embryos  were  inspected  daily  under  a  phase-contrast  dissecting  microscope,  and 
developmental stages were classified according to established methods [43,44]. Under these culture 
conditions, each hatched blastocyst attached to the fibronectin and grew to form a cluster of ICM cells 
over the trophoblastic layer via a process called TE outgrowth. After a total incubation period of   
96 h, morphological scores for outgrowth were estimated. Growing embryos were classified as either 
―attached‖ or ―outgrowth‖, with the latter defined by the presence of a cluster of ICM cells over the 
trophoblastic  layer.  As  described  previously  [45],  ICM  clusters  were  scored  according  to  shape, 
ranging from compact and rounded ICM (+++) to a few scattered cells (+) over the trophoblastic layer. 
4.7. Blastocyst Development Following Embryo Transfer 
To  examine  the  ability  of  expanded  blastocysts  to  implant  and  develop  in  vivo,  the  generated 
embryos  were  transferred  to  recipient  mice.  ICR  females  (white  skin  color)  were  mated  with 
vasectomized males (C57BL/6J; black skin color; from National Laboratory Animal Center, Taiwan, 
ROC) to produce pseudopregnant dams as recipients for embryo transfer. To ensure that all fetuses in 
the  pseudopregnant  mice  came  from  embryo  transfer  (white  color)  and  not  from  fertilization  by 
C57BL/6J (black color), we examined the skin color of the fetuses at day 18 post-coitus. To assess the 
impact  of  DHLA  on  postimplantation  growth  in  vivo,  blastocysts  were  exposed  to  0,  25,  50  and   
100 μM DHLA for 24 h, and then 8 embryos were transferred in parallel to the paired uterine horns of 
day 4 pseudopregnant mice. The surrogate mice were killed on day 18 post-coitus, and the frequency 
of implantation was calculated as the number of implantation sites per number of embryos transferred. 
The incidence rates of resorbed and surviving fetuses were calculated as the number of resorptions or 
surviving fetuses, respectively, per number of implantations. The weights of the surviving fetuses and 
placentae were measured immediately after dissection. 
4.8. Statistics 
The data were analyzed using one-way ANOVA and t-tests and are presented as the mean ±  SEM, 
with significance at P < 0.05. 
5. Conclusions 
Based on these results, we propose that development and preparation of fluorescence nanoparticles 
using DHLA as a capping ligand has a latent ability to cause cytotoxicity and injury in embryonic Int. J. Mol. Sci. 2012, 13  3999 
 
development. However, it appears that concentrations of DHLA lower than 50 μM do not exert a 
hazardous effect on embryonic development. Moreover, our previous study demonstrated that at doses 
of less than 50 μM (0–25 μM), DHLA does not exert hazardous effects on ESC-B5 cell properties, 
including viability, development and differentiation. These findings imply that the DHLA content is 
critical to determine whether or not a particular nanoparticle type is suitable as an in vitro or in vivo 
embryonic development tracer. 
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